Explore the Agenda
7:20 am Check In & Morning Coffee
8:20 am Chair’s Opening Remarks
Unlocking the Future Potential of mRNA from New Applications, Tools & Beyond: The Leadership Perspective
8:30 am In Vivo Immune Cell Programming with mRNA-LNP Therapeutics
- In vivo CAR mRNA-LNP platform selectively generates CAR-T, CAR-NK, and myeloid CAR cells directly in patients
- Clinically validated with data from 50+ patients and demonstrated tolerable repeat dosing
- Best-in-class in vivo CARs across oncology and autoimmunity, including first clinical responses with in vivo CARs outside blood cancers
9:00 am CEO & mRNA Leaders Think Tank: From CAR-T Platforms, Gene Editing Triumphs & Cancer Immunotherapy Clinical Advances; Navigating mRNA’s Potential into New Therapies & Tools Towards Better Drugs for Patients Faster
- What are the future opportunities, promising targets and applications on the horizon for mRNA to achieve commercial success?
- How are recent mRNA and LNP platform acquisitions fueling next generation innovations from science to strategy?
- Linear, circular, self-amplifying, trans-amplifying RNA – Which modality offers the most efficiency?
- With clinical trials moving towards the far East and Australia, what opportunities does this open for the mRNA industry to progress faster to clinical validation?
10:00 am Morning Break & Speed Networking
This networking session is your opportunity to get face-to-face with many of the brightest minds working in the mRNA field and establish meaningful business relationships to pursue for the rest of the conference
Discovery
Optimizing mRNA Design to Enable Stable & Efficacious Therapies Products for Infectious & Rare Diseases
11:00 am Engineering Next Generation mRNA-Based Therapeutic Proteins to Advance Infectious & Rare Disease Therapy Portfolios
Director of RNA Therapeutics, AstraZeneca
- Providing an overview of the mRNA platform
- Case Study Presentation: mRNA encoded IgGs/VHHs for the treatment of infectious diseases
- Case Study Presentation: Engineering next generation cas9 proteins to advance rare disease therapies
11:30 am Closing the Loop in mRNA Therapeutics with AI-Driven Design–Make–Test Workflow
- AI-driven RNA design accelerates optimization of UTRs, structure, and therapeutic potency
- Rapid prototyping enables efficient iteration from design to drug substance
- Sequencing-based validation closes the loop by connecting RNA quality attributes to functional outcomes
12:00 pm This talk will highlight these important themes:
CTO & Professor, Ribotech
- AI-guided multimodal mRNA optimization strategy
- Combining state-of-the-art biology and AI
- Protein sequence context guided mRNA optimization
Pre-Clinical & Clinical Development
Manufacturing & CMC
1:00 pm General Lunch Break & Networking
1:00 pm Private Hosted Lunch (By Invitation Only)
Discovery
Unlocking mRNA-LNP Chemistry Through Novel Innovations to Enhance Delivery Across Therapy & Vaccine Indications
2:00 pm Next-Gen LNPs: The Future of Effective mRNA Vaccines
Director & Senior Scientist - Chemistry, Translate Bio-A Sanofi Company
- A comprehensive overview of Sanofi’s next-generation mRNALNPs for the potential vaccine applications
- Discovery Story of Morpholino Lipids: A novel ionizable lipid class for enhanced mRNA delivery
- Establishing a proprietary mRNA vaccine platform through comprehensive optimization of all four mRNA-LNP components
2:30 pm Stable In Vivo Expression of Monoclonal Antibody from Lyophilized mRNA–LNPs Stored at Room Temperature
Associate Principal Scientist, AstraZeneca
- Lyophilized mRNA–LNPs engineered for room‑temperature storage, maintaining physicochemical integrity, good in vitro transfection, and stable in vivo monoclonal antibody expression
- LNP internal structure determined for lyophilized formulations with different cryoprotectants and buffers using SAXS and cryo‑EM, linking structure to performance
3:00 pm Afternoon Break & Poster Session
As the landscape of innovation that is supercharging the next wave of efficacious mRNA therapeutics and vaccines, it is more important than ever to collaborate and learn for the growth of this field.
Join our dedicated poster session to share your latest data and get the first look into what your peers are working on!
Unravelling Novel RNA Modality Approaches to Improve Potency, Tolerability & Protein Expression
3:45 pm Development of Trans-Amplifying RNAs to Enable Robust Expression Across Multiple Species
Chief Executive Officer, Amplitude Therapeutics
- Trans-amplifying RNA (taRNA) combines the advantages of modified mRNA and self-amplifying RNAs
- taRNA leads to increased peak expression as compared to modified mRNA at a fraction of the total RNA dose
- Multiple datasets demonstrating the potency, tolerability, and species translatability of taRNA
4:15 pm Cell-Type-Specific Delivery Beyond In Vivo CAR-T
President, SunVax mRNA Therapeutics
- Ionizable lipids suitable for cell type specific delivery
- Delivery efficacies beyond LNP
- Applications of cell-type-specific delivery beyond in vivo CAR-T
Pre-Clinical & Clinical Development
Manufacturing & CMC